JP2019502694A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019502694A5 JP2019502694A5 JP2018531487A JP2018531487A JP2019502694A5 JP 2019502694 A5 JP2019502694 A5 JP 2019502694A5 JP 2018531487 A JP2018531487 A JP 2018531487A JP 2018531487 A JP2018531487 A JP 2018531487A JP 2019502694 A5 JP2019502694 A5 JP 2019502694A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- amino acid
- acid sequence
- polypeptide
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 372
- 229920001184 polypeptide Polymers 0.000 claims description 365
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 365
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 310
- 235000001014 amino acid Nutrition 0.000 claims description 185
- 229940024606 amino acid Drugs 0.000 claims description 176
- 150000001413 amino acids Chemical class 0.000 claims description 146
- 239000000427 antigen Substances 0.000 claims description 116
- 102000036639 antigens Human genes 0.000 claims description 116
- 108091007433 antigens Proteins 0.000 claims description 116
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 65
- 238000005734 heterodimerization reaction Methods 0.000 claims description 56
- 239000012634 fragment Substances 0.000 claims description 37
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 31
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 24
- 239000004472 Lysine Substances 0.000 claims description 24
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 14
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims description 14
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 14
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 14
- 230000004988 N-glycosylation Effects 0.000 claims description 14
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 14
- 239000004473 Threonine Substances 0.000 claims description 14
- 125000000539 amino acid group Chemical group 0.000 claims description 14
- 229960001230 asparagine Drugs 0.000 claims description 14
- 235000009582 asparagine Nutrition 0.000 claims description 14
- 239000000539 dimer Substances 0.000 claims description 13
- 108060003951 Immunoglobulin Proteins 0.000 claims description 11
- 229940094342 human immunoglobulin m Drugs 0.000 claims description 11
- 102000018358 immunoglobulin Human genes 0.000 claims description 11
- 230000035772 mutation Effects 0.000 claims description 9
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 7
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 7
- 235000018417 cysteine Nutrition 0.000 claims description 7
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 7
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 7
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 6
- 239000002202 Polyethylene glycol Substances 0.000 claims description 6
- 229960000310 isoleucine Drugs 0.000 claims description 6
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 239000000833 heterodimer Substances 0.000 claims description 3
- 210000004899 c-terminal region Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021092180A JP2021121642A (ja) | 2015-12-18 | 2021-06-01 | 二特異性抗体基幹 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562269664P | 2015-12-18 | 2015-12-18 | |
| US62/269,664 | 2015-12-18 | ||
| PCT/US2016/066865 WO2017106462A1 (en) | 2015-12-18 | 2016-12-15 | Bispecific antibody platform |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092180A Division JP2021121642A (ja) | 2015-12-18 | 2021-06-01 | 二特異性抗体基幹 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019502694A JP2019502694A (ja) | 2019-01-31 |
| JP2019502694A5 true JP2019502694A5 (https=) | 2020-01-16 |
| JP7138046B2 JP7138046B2 (ja) | 2022-09-15 |
Family
ID=57681809
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531487A Active JP7138046B2 (ja) | 2015-12-18 | 2016-12-15 | 二特異性抗体基幹 |
| JP2021092180A Pending JP2021121642A (ja) | 2015-12-18 | 2021-06-01 | 二特異性抗体基幹 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021092180A Pending JP2021121642A (ja) | 2015-12-18 | 2021-06-01 | 二特異性抗体基幹 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11447575B2 (https=) |
| EP (1) | EP3389710A1 (https=) |
| JP (2) | JP7138046B2 (https=) |
| KR (1) | KR20180100136A (https=) |
| CN (1) | CN108601830B (https=) |
| AU (1) | AU2016370821A1 (https=) |
| CA (1) | CA3008840A1 (https=) |
| MA (1) | MA44054A (https=) |
| WO (1) | WO2017106462A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018037092A1 (en) * | 2016-08-26 | 2018-03-01 | Sanofi | Multispecific antibodies facilitating selective light chain pairing |
| KR102794369B1 (ko) | 2017-08-01 | 2025-04-15 | 에이비 테라퓨틱스 인코퍼레이티드 | 이중특이 항체 및 그의 용도 |
| CN110028588A (zh) * | 2018-01-11 | 2019-07-19 | 上海细胞治疗研究院 | 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用 |
| US20220089704A1 (en) | 2018-10-29 | 2022-03-24 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
| EP3897851A2 (en) | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
| US12463463B2 (en) | 2019-01-28 | 2025-11-04 | Ab Therapeutics, Inc. | Bispecific antibodies and uses thereof |
| US20220227827A1 (en) * | 2019-03-25 | 2022-07-21 | Dingfu Biotarget Co., Ltd. | Proteinaceous heterodimer and use thereof |
| US12077603B2 (en) * | 2019-08-15 | 2024-09-03 | Regeneron Pharmaceuticals, Inc. | Multispecific antigen-binding molecules for cell targeting and uses thereof |
| US20220306760A1 (en) * | 2019-08-23 | 2022-09-29 | Igm Biosciences, Inc. | Igm glycovariants |
| MX2022003507A (es) * | 2019-09-25 | 2022-04-25 | Univ Stuttgart | Modulos de union que comprenden dominios ehd2 modificados. |
| WO2021139758A1 (zh) * | 2020-01-09 | 2021-07-15 | 江苏恒瑞医药股份有限公司 | 新型多肽复合物 |
| CN113307879A (zh) * | 2020-02-27 | 2021-08-27 | 启愈生物技术(上海)有限公司 | 一种taa/ctla-4/il15三功能融合蛋白及其应用 |
| CN113563473A (zh) * | 2020-04-29 | 2021-10-29 | 三生国健药业（上海）股份有限公司 | 四价双特异性抗体、其制备方法和用途 |
| WO2022096704A1 (en) * | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
| CA3219388A1 (en) * | 2021-05-14 | 2022-11-17 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Antigen-binding molecule |
| JP2024527977A (ja) | 2021-07-27 | 2024-07-26 | ノヴァブ， インコーポレイテッド | 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体 |
| JP2025532897A (ja) * | 2022-09-28 | 2025-10-03 | ドレン バイオ， インコーポレイテッド | 多重特異性抗体及びその使用方法 |
| WO2025042806A2 (en) | 2023-08-21 | 2025-02-27 | Modernatx, Inc. | C-met binding antibodies, nucleic acids encoding same, and methods of use |
| WO2026044055A1 (en) | 2024-08-23 | 2026-02-26 | Modernatx, Inc. | Muc16 binding molecules, nucleic acids encoding same, and methods of use |
| WO2026075820A1 (en) | 2024-10-03 | 2026-04-09 | Modernatx, Inc. | 4-1bb binding molecules, nucleic acids encoding same, and methods of use |
| CN121148519B (zh) * | 2025-11-18 | 2026-02-13 | 西北农林科技大学 | 基于计算模拟辅助的双特异性抗体分子设计与优化方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) * | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| MX342034B (es) * | 2011-02-28 | 2016-09-12 | Hoffmann La Roche | Proteinas monovalentes que se unen a antigenos. |
| WO2013012733A1 (en) * | 2011-07-15 | 2013-01-24 | Biogen Idec Ma Inc. | Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto |
| WO2013156054A1 (en) * | 2012-04-16 | 2013-10-24 | Universität Stuttgart | The igm and ige heavy chain domain 2 as covalently linked homodimerization modules for the generation of fusion proteins with dual specificity |
| MX2014014162A (es) * | 2012-05-24 | 2015-02-04 | Hoffmann La Roche | Anticuerpos multiespecificos. |
| CA2926853C (en) * | 2013-10-18 | 2022-04-26 | Regeneron Pharmaceuticals, Inc. | Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody |
| WO2016087650A1 (en) * | 2014-12-05 | 2016-06-09 | Merck Patent Gmbh | Domain-exchanged antibody |
| WO2017011342A1 (en) | 2015-07-10 | 2017-01-19 | Abbvie Inc. | Igm-or-ige-modified binding proteins and uses thereof |
| WO2018037092A1 (en) * | 2016-08-26 | 2018-03-01 | Sanofi | Multispecific antibodies facilitating selective light chain pairing |
| EP3897851A2 (en) * | 2018-12-17 | 2021-10-27 | Revitope Limited | Twin immune cell engager |
-
2016
- 2016-12-15 WO PCT/US2016/066865 patent/WO2017106462A1/en not_active Ceased
- 2016-12-15 CN CN201680081272.6A patent/CN108601830B/zh active Active
- 2016-12-15 CA CA3008840A patent/CA3008840A1/en active Pending
- 2016-12-15 KR KR1020187020661A patent/KR20180100136A/ko not_active Abandoned
- 2016-12-15 US US16/061,903 patent/US11447575B2/en active Active
- 2016-12-15 JP JP2018531487A patent/JP7138046B2/ja active Active
- 2016-12-15 EP EP16820131.7A patent/EP3389710A1/en active Pending
- 2016-12-15 MA MA044054A patent/MA44054A/fr unknown
- 2016-12-15 AU AU2016370821A patent/AU2016370821A1/en not_active Abandoned
-
2021
- 2021-06-01 JP JP2021092180A patent/JP2021121642A/ja active Pending